Appellis CEO Cedric Francois delivered an update on his company’s fully enrolled Phase III Filly trial of APL-2, a peptide targeting the C3 inhibitor in the complement cascade as a treatment for geographic atrophy. The 246 patients in the trial have been divided into three groups – those who receive the treatment once a month, those receiving it every other month, and those in the sham arm of the study. By inhibiting complement, Apellis hopes to disrupt the formation of GA. Patients in the Filly trial will be tested to see if the pace of GA is slowing. Apellis will also test for telltale blood markers that would measure success. The primary endpoint is the change in square root GA lesion size from baseline at month 12 as measured by fundus autofluorescence (FAF). Francois says the company anticipates reading out the results in September 2017 and hopes to report at next year’s American Academy of Ophthalmology (AAO) meeting.
Cedric Francois, MD, PhD
Dr. Francois is a co-founder of Apellis and has served as a member of our board of directors and as our President and Chief Executive Officer since September 2009.